Skip to main content Back to Top


Tropicamide 1% Ophthalmic Solution

Products Affected - Description

    • Tropicamide ophthalmic solution, Sandoz, 1%, 3 mL bottle, 1 count, NDC 61314-0355-01

Reason for the Shortage

    • Akorn did not provide a reason for the shortage.
    • Alcon has Mydriacyl available.
    • Bausch Health discontinued tropicamide 1% ophthalmic drops in mid-2018.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • Mydriacyl ophthalmic solution, Alcon Labs, 1%, 15 mL bottle, 1 count, NDC 00065-0355-15
    • Tropicamide ophthalmic solution, Akorn, 1%, 15 mL bottle, 1 count, NDC 17478-0102-12
    • Tropicamide ophthalmic solution, Sandoz, 1%, 15 mL bottle, 1 count, NDC 61314-0355-02

Estimated Resupply Dates

    • Sandoz has tropicamide 1% solution in 3 mL bottles on back order and the company estimates a release date of late-May 2019.


Updated May 14, 2019 by Anthony Trovato, PharmD, BCPS. Created March 20, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins